Covid-vaccine maker, Novavax Inc. (NVAX) reported a massive revenue jump and swung to profitability in the first quarter of 2025, supported by strategic partnerships, licensing deals, and cost controls.
Q1, 2025 Performance:
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com